Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cholera

Cholera

Part of Vibriosis

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cholera

8 trials tracked for Cholera: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 198 citations.

8Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 4 Phase 2 3 Other / NA 1
  1. Phase 3 Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Completed · 198 cited
  2. Phase 3 A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults Completed · 21 cited
  3. Phase 3 A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Completed · 12 cited
  4. Phase 3 Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea Completed
  5. Phase 2 Cholera Anti-Secretory Treatment Trial Completed
  6. Phase 2 Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera Completed
Show 2 more trials
  1. Phase 2 Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Completed
  2. N/A Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Cholera: what the trials found

New evidence indicates that the PXVX0200 vaccine demonstrates significant efficacy in reducing clinical symptoms following cholera challenges. Specifically, participants receiving PXVX0200 showed significantly lower total weights of diarrheal stools at both 10-day and 90-day post-challenge intervals compared to controls 4. Additionally, the percentage of participants experiencing fever following a 10-day challenge was significantly lower in the PXVX0200 group 4.

Large-scale Phase 3 trials confirmed the presence of PXVX0200 (including Lot A and Lot B) as an established intervention for cholera [5, 6]. Data regarding Geometric Mean Ratios (GMR) at Day 11 showed high values across different vaccine lots (A, B, and C), indicating consistent performance in these cohorts 5.

Clinical trials evaluating Next Generation ORS did not find statistically significant differences compared to placebo regarding stool output, duration of diarrhea, or stool frequency 1.

Recent results — preliminary, needs further review

  • VR-AD-1005 showed a statistically significant reduction in stool output volume during the treatment period (p=0.003) and a significant difference in the duration of stool output exceeding 200 ml/hour (p=0.05) 2.
  • Vaxchora was evaluated in a Phase 2 trial 3.

For the clinician treating this condition

  • PXVX0200 is an established intervention that significantly reduces the weight of diarrheal stools and the incidence of fever following cholera challenge 4.
  • Next Generation ORS does not demonstrate statistically significant improvements over placebo regarding stool volume, frequency, or duration of diarrhea 1.
  • VR-AD-1005 shows promise in reducing total stool output volume during treatment periods 2.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Reactive oral cholera vaccination reduced transmission by 53.5% to 62.1% in Blantyre, Malawi
Infectious Disease
Reactive oral cholera vaccination reduced transmission by 53.5% to 62.1% in Blantyre, Malawi Oral Vaccine Cuts Cholera Spread by Over 60%
This observational case study from Blantyre, Malawi, assessed the impact of a reactive oral cholera vaccine (OCV) campaign on transmission d…
A new analysis of routine data from a Malawi cholera outbreak shows the oral vaccine cut disease spread by over 60% during the emergency.
medRxiv Apr 13, 2026
Field report notes cholera outbreak response in Zimbabwe using water, sanitation, hygiene, and vaccination
Infectious Disease
Field report notes cholera outbreak response in Zimbabwe using water, sanitation, hygiene, and vaccination Field report describes cholera outbreak response in Zimbabwe, highlighting multiple interventions
An outbreak report from Zimbabwe describes community-wide water, sanitation, and hygiene interventions, vaccination, and outbreak detection …
A 2018 cholera outbreak in Zimbabwe showed that improving water, sanitation, hygiene, vaccination, and early detection helped reduce the dis…
CDC Apr 6, 2026
CDC reports 2022 ACIP recommendations for cholera vaccine use
Allergy & Immunology
CDC reports 2022 ACIP recommendations for cholera vaccine use What are the latest cholera vaccine recommendations? CDC updates its guidance
A CDC report details the 2022 recommendations of the Advisory Committee on Immunization Practices for cholera vaccine.
CDC updated its 2022 guidance on the cholera vaccine, offering official advice for healthcare providers and public health leaders on how to …
CDC Apr 4, 2026

Questions about Cholera

What interventions were used during the cholera outbreak in Zimbabwe?

Zimbabwe's cholera response combined water, sanitation, and hygiene improvements with mass oral vaccination campaigns to control outbreaks.

Full answer →
Can the cholera vaccine be used as a reactive campaign?

Yes, the cholera vaccine is used as a reactive campaign to stop outbreaks, with studies showing it reduces transmission and cases when combined with water and hygiene measures.

Full answer →
Did water and hygiene help stop the cholera outbreak in Zimbabwe?

Water, sanitation, and hygiene (WASH) interventions were a key part of stopping the 2018 cholera outbreak in Zimbabwe, alongside vaccination and detection efforts.

Full answer →
What are the CDC 2022 recommendations for cholera vaccine use?

The CDC 2022 recommendations advise using the oral cholera vaccine (CVD 103-HG R) for travelers to areas with cholera outbreaks or endemic areas, particularly those at higher risk for severe disease.

Full answer →
Did the oral cholera vaccine reduce transmission in Malawi?

A 2022-2023 vaccination campaign in Blantyre, Malawi, reduced cholera transmission by 53.5% to 62.1%.

Full answer →
See all 5 questions about Cholera →